Reinhardt; Gerard E. - US Patent Attorneys and Agents

Attorney: Reinhardt; Gerard E.

Number of patents: 20
Last date: October 11, 2011

Browse patents
Browse applications

Number	Title	Issue Date
8034933	Piperidine derivatives useful as CCR5 antagonists The present invention provides a compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R9, R10, A and B are as defined i...	10/11/2011
7825121	Piperazine derivatives useful as CCR5 antagonists The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R	11/02/2010
7772276	Exo-selective synthesis of himbacine analogs This application discloses a novel process for the synthesis of himbacine analogs, as well as the compounds produced thereby. The synthesis proceeds by alternative routes including the cyclic ketal amide route, the chiral carbamate amide route, and the chiral carbam...	08/10/2010
7713999	Thrombin receptor antagonists Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt thereof, wherein: the dotted line represents an optional single bond; represent...	05/11/2010
7511062	Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors The invention claims compounds of the formula wherein is a 5-membered heteroaryl; X is S or O; R1 is H, alkyl...	03/31/2009
7498438	Fused ring NKantagonists A compound having the general structure shown in Formula 1: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example variou...	03/03/2009
7488742	Thrombin receptor antagonists A series of compounds represented by the structural formulas and pharmaceutically acceptable isomers, salts, solvates and polymorphs thereof are disclosed. Also disclosed are pharmaceutical composi...	02/10/2009
7485645	17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17β-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing...	02/03/2009
7442712	Constrained himbacine analogs as thrombin receptor antagonists A compound represented by the structural formula and pharmaceutically acceptable salts and solvents thereof is disclosed, wherein: the single-dashed line	10/28/2008
7312223	Metabolite of xanthine Phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction The present invention is directed to a metabolite of a xanthine Phosphodiesterase type 5 inhibitor having the following structure derivatives, and formulations thereof, and processes for preparing the same. ...	12/25/2007
7271174	Metabolites of tricyclic amides useful for inhibition of G-protein function and methods of treatment of proliferative diseases The present invention relates to metabolites of tricyclic amides, and structurally related compounds, represented by the structural formula (I): and pharmaceutically acceptable isomers, s...	09/18/2007
7235567	Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist A crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist compound, which exhibits a powder x-ray diffraction profile substantially the same as that shown in FIG. 1, or which exhibits a differential scanning calorimtery profile substantial...	06/26/2007
7192962	Xanthine phosphodiesterase V inhibitor polymorphs Crystalline polymorphs of 1-ethyl-3,7-dihydro-8-[(1R,2R) -(hydroxycyclopentyl)amino]-3-(2-hydroxyethyl)-7-[(3-bromo-4-methoxyphenyl)methyl]-1H-Purine-2,6-dione in Form 1 and Form 2, which exhibit x-ray powder diffraction profiles substantially the same as those show...	03/20/2007
7074923	Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof A process for preparing xanthine phosphodiesterase V inhibitors, and compounds utilized in said process. The process includes a five-step methodology for efficient synthesis of Compound 5 without intermediate purifications or separations, a dihalogenation step to sy...	07/11/2006
7037920	Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salts thereof, wherein: n1 and n2 are independently 0-2; Het...	05/02/2006
6969719	Polycyclic guanine phosphodiesterase V inhibitors A polycyclic guanine phosphodiesterase V inhibitor having the formula (I.1) or (II.1), with the variables defined herein, which is useful for treating sexual dysfunction and other physiological disorders: A representativ...	11/29/2005
6958337	Crystalline antifungal polymorph The crystalline polymorph Form I of (−)-4-[4-[4-[4-[[(2R-cis)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)furan-3-yl]methoxy]phenyl]-1-piperazinyl]phenyl-2,4-dihydro-2-[(S)-1-ethyl-2(S)-hydroxylpropyl]-3H-1,2,4-triazol-3-one represented by the ...	10/25/2005
6943171	Polycyclic guanine derivative phosphodiesterase V inhibitors A compound having the formula (Ia) or (b), salt or solvate thereof, with the variables as defined herein, which can inhibit selectively phosphodiesterase V and can be useful for treating sexual dysfunction and other physiological disorders, symptoms and diseases:	09/13/2005
6894040	Xanthine phosphodiesterase V inhibitors A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders:	05/17/2005
6894065	Thrombin receptor antagonists Heterocyclic-substituted compounds of the formula or a pharmaceutically acceptable salt thereof, are disclosed, wherein: Z is —(CH2)n—;	05/17/2005

PatentStorm

Quotables

PatentStorm News

Attorney: Reinhardt; Gerard E.